


UCSF Translational HIV Research



Productivity Mostly Attributable to Data and Biological Specimens from the Cohorts

	SCOPE	UARTO	ISS Clinic
No. of subjects	1938	750	22,087
Location	San Francisco	Mbarara, Uganda	Mbarara, Uganda
Cohort type	Dynamic	Fixed	Dynamic
Entry Criteria	Demand-driven collection of both prototypical & rare clinical phenotypes	Consecutive ART starters at a prototypical municipal ART clinic	All patients at a prototypical municipal ART clinic
Paper-based measurements	Research-dedicated	Research-dedicated	During course of clinical care
Biologic specimens	Serum, plasma, PBMCs, saliva	Serum, plasma, PBMCs, saliva	--
Follow-up	4 months	4 months	Clinically-driven
Special procedures	Gut & lymph node biopsies, apheresis	Real time adherence monitoring	Active tracking of drop outs

UARTO – Ugandan Cohort



San Francisco Cohorts

- **SCOPE: Chronically HIV-infected patients**
 - Enriched for “extreme phenotypes” (elite controllers, viremic non-progressors, immunologic non-responders, etc).
 - Key Faculty: Steve Deeks, Jeff Martin, Peter Hunt

Cohort/specimens/data now merged with . . .


- **OPTIONS (historic): Recently HIV-infected patients**
 - Boutique Cohorts: Transmission pairs, Highly exposed HIV-uninfected patients
 - Key Faculty: Rick Hecht, Chris Pilcher, Michael Busch
- **Treat Acute (new): Acutely HIV-infected patients**
 - “Getting to Zero” SF campaign, <100 days from estimated date of HIV infection, PreP failures, HIV-1 Ab neg/plasma VL positive
 - Key faculty: Sulggi Lee, Steve Deeks, Tim Henrich

UCSF Treat Acute Study

- **New HIV diagnosis**
- Negative HIV test in past 3-6 months
- Suspected exposure in last 90 days
- ART naïve (recently ~1 wk started ok)


- Study provides:
 - Descovy + Dolutegravir immediately x 6 months
 - Monthly visits – labs, close f/u, for 6 months

Week




Clinical Cohorts

- **WIHS: Multi-center cohort of HIV-infected women and risk-matched HIV-negative controls**
 - Currently: 3677 HIV+ women and 1305 HIV- women
 - Key Faculty: Phyllis Tien
 - Recent merge of WIHS with MACS (men)
 - Now expansion to southern states



Domestic Cohort Linkages




ites

Baltimore, MD	Galveston, TX	Pittsburgh, PA
Birmingham, AL	Greenboro, NC	Portland, OR
Boston, MA	Honolulu, HI	Providence, RI
Brook, NY	Houston, TX	Rochester, NY
Brooklyn, NY	Indianapolis, IN	Sacramento, CA
Buffalo, NY	Iowa City, IA	San Diego, CA
Chapel Hill, NC	Kansas City, MO	San Juan, PR
	Los Angeles, CA	San Francisco, CA
Chicago, IL	Miami, FL	San Leandro, CA
Cincinnati, OH	Minneapolis, MN	San Rafael, CA
Cleveland, OH	Nashville, TN	Seattle, WA
Columbus, OH	New Orleans, LA	St. Louis, MO
Dallas, TX	New York, NY	Stanford, CA
Denver, CO	Oakland, CA	Stony Brook, NY
Detroit, MI	Omaha, NE	Tampa, FL
Durham, NC	Philadelphia, PA	Torrance, CA
		Washington, DC

Canada
 British Columbia: Vancouver
 Ontario: Hamilton, Kingston, London, Ottawa, Sudbury, Thunder Bay, Toronto
 Quebec: Montreal
 Southern Alberta

International Cohort Linkages



Other Research Networks

- **ACTG (AIDS Clinical Trials Group)**
 - Diane Havlir (TB TSG Vice Chair)
 - Peter Hunt (Inflammation/End-organ Disease Chair)
- **CNICS (CFAR Network of Integrated Clinical Systems)**
 - Linked electronic medical records across multiple HIV clinics
 - Specimens available to link biomarkers to rare clinical outcomes
 - Key Faculty: Elvin Geng, Steve Deeks, Peter Hunt, Jeff Martin

Core Metrics: 2012-2013

Item	Number
Projects	
Total	144
International	33
Users	
Total	205
UCSF CFAR	69
Other CFARs	57
Non-CFAR	79
Early Stage Investigators	38
Publications*	60
Conference Presentations	58

* including submitted

Real time inventory

Participant Classification	Number of Participants with at least 1 applicable timepoint	Number of Timepoints with at least 1 available aliquot	Total Number of Available Aliquots
Elite Controller--Confirmed	60	448	4637
Viremic Controller--Confirmed	116	734	8687
"Generic" Controller--Confirmed	168	1425	16122
Non-Controller	279	844	8793
HAART Suppressed	622	4038	47298
Elite Controller--Awaiting Further Observation	35	64	700
Viremic Controller--Awaiting Further Observation	87	172	2130
"Generic" Controller--Awaiting Further Observation	109	227	2696

Rapid distribution

**2012:
48 separate specimen
shipments to
investigators**

Specimen Type	No. Unique Timepoints
Plasma	2080
Serum	450
Viable PBMC	947
Non-viable PBMC	768

Innovation: Linkage to CNICS Specimen Repository

- March 25, 1987 to present
- 8 contributing sites
 - CWRU
 - JHU
 - UCSD
 - UNC
 - Fenway
 - UAB
 - UCSF
 - UW
- 661,880 aliquots
 - from 77,819 unique timepoints
 - from 11,414 HIV-infected patients

